Study Overview and Key Findings

Researchers tested THC and Mira-55, along with rimonabant's ability to reverse their effects, in the same study using three standard measures scientists use to characterize THC-like activity: body temperature, movement, and muscle rigidity (Catalepsy). They also tested for anxiety-like behavior.

THC showed the classic pattern of a THC-like compound. It lowered body temperature, slowed movement, and catalepsy- and all three effects went away when rimonabant was given alongside it. That is the textbook signature researchers look for to confirm a compound is acting through the same CB1 pathway as THC.

Mira-55 showed a different pattern. It produced only one of those three effects, a modest drop in body temperature, with no effect on movement or rigidity.

Mira-55's mechanism looks different, too. Rimonabant did not block Mira-55's effect on body temperature the way it blocked THC's, suggesting Mira-55 is not working through the same mechanism as THC, even in the one area where their effects briefly overlap.

Mira-55 produced a meaningful effect; THC did not: it reduced anxiety-like behavior. Rimonabant made animals more anxious in this test; Mira-55 made them less anxious - consistent with what MIRA reported in March, and a distinguishing feature of Mira-55's profile rather than simply an absence of THC-like effects.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.